News
Portfolio Company News
- March 18, 2013
Trevena to Present First-In-Man Study Results for Mu-Opioid Biased Ligand TRV130
- March 13, 2013
Ceregene and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase II Trial
- March 13, 2013
Vertiflex®, Inc. Announces Sale of Certain Non-Core Spinal Implant Technologies to Stryker
- March 12, 2013
FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
- March 12, 2013
Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
- March 05, 2013
BioWorld Today: News to Note - Lithera, Inc. - March 05, 2013
Silence Therapeutics Receives Formal Approval from the German Authorities (BfArM) for its Phase Ib/IIa Combination Trial into Pancreatic Cancer
- March 04, 2013
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System for Post-Operative Pain in Major Open Abdominal Surgery Patients
- February 26, 2013
Medical Device Daily: Product Briefs - PnuemRx, Inc. - February 26, 2013
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™
- February 25, 2013
Ablynx and Spirogen Enter Into a Research Collaboration to Evaluate the Potential of Novel Toxin-Nanobody Drug Conjugates in Cancer
- February 19, 2013
Data Demonstrating the Safety and Efficacy of Chimerix’s Antiviral CMX001 Presented at BMT Tandem Meetings
- February 13, 2013
Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety and Efficacy Results in a Phase II Clinical Trial in Rheumatoid Arthritis
- February 10, 2013
Nanōmix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
- February 07, 2013
Innate Pharma Reports Increase in Annual Revenue for 2012
- February 06, 2013
Medical Device Daily: Med-Tech Notes - Carbylan BioSurgery, Inc. - February 05, 2013
Portola Enters into Clinical Collaboration Agreement with Bayer and Janssen for Phase 2 Study of Universal Factor Xa Inhibitor Antidote, PRT4445, and XARELTO®
- January 29, 2013
Portola and Lee’s Pharmaceutical Enter into Agreement to Expand Phase 3 APEX Study of Betrixaban into China
- January 23, 2013
Trevena, Inc. - JPET publication describes the discovery and activity of TRV130
- January 21, 2013
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
< Previous | Next >
